There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AnaptysBio Inc (ANAB), Autolus Therapeutics Plc (AUTL) and Cara Therapeutics (CARA) with bullish sentiments.
AnaptysBio Inc (ANAB)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on AnaptysBio Inc, with a price target of $126. The company’s shares closed on Friday at $51, close to its 52-week low of $47.73.
According to TipRanks.com, Fein is a 3-star analyst with an average return of 0.7% and a 40.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
AnaptysBio Inc has an analyst consensus of Moderate Buy, with a price target consensus of $100.60.
See today’s analyst top recommended stocks >>
Autolus Therapeutics Plc (AUTL)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Autolus Therapeutics Plc today and set a price target of $24. The company’s shares closed on Friday at $11.33, close to its 52-week low of $10.76.
According to TipRanks.com, Chattopadhyay is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.7% and a 38.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.
Autolus Therapeutics Plc has an analyst consensus of Moderate Buy, with a price target consensus of $24, which is an 111.8% upside from current levels. In a report issued on August 8, William Blair also maintained a Buy rating on the stock.
Cara Therapeutics (CARA)
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Cara Therapeutics today and set a price target of $30. The company’s shares closed on Friday at $23.37.
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 6.7% and a 51.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Collegium Pharmaceutical.
Currently, the analyst consensus on Cara Therapeutics is a Strong Buy with an average price target of $34, which is a 45.5% upside from current levels. In a report issued on July 30, Piper Jaffray also maintained a Buy rating on the stock with a $39 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
